News and Events

Mutant RAS can shift other proteins’ positions inside cancer cells

Mutant RAS proteins help shuttle other proteins out of the cell nucleus and into the cytoplasm, where some can promote cancerous growth.

Clinical trial researching combination drug therapy for Ewing sarcoma and rhabdomyosarcoma

A clinical trial led by Christine M. Heske, M.D., Investigator in the Pediatric Oncology Branch, is researching combination drug therapy for adolescents and young adults with Ewing sarcoma and rhabdomyosarcoma.

Clinical trial researching drug therapy for adults with colorectal or gastroesophageal cancer

A clinical trial led by Nicholas D. Klemen, M.D., Physician-Scientist Early Investigator in the Surgery Branch, is researching drug therapy for adults with colorectal or gastroesophageal cancer.

Clinical trial researching drug therapy for adults with HIV-related diseases

A clinical trial led by Ramya Ramaswami, M.B.B.S., M.P.H., Lasker Clinical Research Scholar in the HIV and AIDS Malignancy Branch, is researching drug therapy for two HIV-related diseases.

Clinical trial researching CAR T-cell therapy for leukemia and lymphoma

A clinical trial led by Jennifer N. Brudno, M.D., Associate Research Physician in the Surgery Branch, is researching CAR T-cell therapy for chronic lymphocytic leukemia and small lymphocytic lymphoma.

Clinical trial researching combination drug therapy for genitourinary tumors

A clinical trial led by Andrea B. Apolo, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is researching combination drug therapy for rare genitourinary tract tumors.

Chuan Wu appointed to Senior Investigator at CCR

The CCR community congratulates Chuan Wu, M.D., Ph.D., who has been appointed Senior Investigator in the Experimental Immunology Branch. Wu studies the role of intestinal neuroimmune interactions in health and disease. His lab works to understand the cellular and molecular mechanisms of the dynamic interplay between the enteric nervous system and the immune system to build a comprehensive view of intestinal homeostasis and to discover new therapeutics for intestinal inflammatory diseases.

Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer

Results from a large CCR clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following surgical removal of the bladder. Researchers led by Andrea B. Apolo, M.D., Senior Investigator in the Genitourinary Malignancies Branch, found that postsurgical treatment with pembrolizumab (Keytruda), which is approved by the Food and Drug Administration (FDA) for treating at least 18 different cancers, was superior compared with observation.

NIH study links neighborhood environment to prostate cancer risk in men with West African genetic ancestry

CCR researchers led by Stefan Ambs, Ph.D., M.P.H., Senior Investigator in the Laboratory of Human Carcinogenesis, found that West African genetic ancestry was associated with increased prostate cancer among men living in disadvantaged neighborhoods but not among men living in more affluent neighborhoods. The findings suggest that neighborhood environment may play a role in determining how genetic ancestry influences prostate cancer risk.

Opting for a Novel Combination Treatment for Resistant Aggressive B-Cell Lymphoma

In 2020, Justin enrolled in a CCR trial testing a five-drug combination treatment called ViPOR for non-Hodgkin lymphoma. Four years later, his doctor Christopher J. Melani, M.D., Assistant Research Physician in the Lymphoid Malignancies Branch, describes Justin as likely cancer-free.

Breadcrumb